Name of Study: Phase II Study of Gemcitabine and nab-Paclitaxel in Combination with Vismodegib (GDC-0449;Hedgehog Inhibitor) in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This trial for pancreatic cancer uses chemotherapy together with a medication (GDC-0449) that inihbits a protein called Hedgehog. The Hedgehog protein has recently been found to foster the growth of pancreatic cancer cells. The drug GDC-0449 is given along with chemotherapy agents.
This study includes tests that attempt to better understand this therapy, including pre and post treatment biopsies. The safety of GDC-0449 when combined with gemcitabine and nab-paclitaxel (Abraxane) will also be assessed.
Participants will receive Gemcitabine, nab-Paclitaxel, GDC-0449.